Board of Directors
Robert L. Zerbe, M.D.
Chairman since October 2012
Director since January 2006
Dr. Robert Zerbe joined the Vericel Board of Directors in January 2006 and has been its Chairman since October 2012. Until July 2016, Dr. Zerbe served as the Chief Executive Officer of QUATRx Pharmaceuticals Company, a venture‑backed drug development company, which he co‑founded in 2000. Prior to his role at QUATRx, Dr. Zerbe held several senior executive management positions with major pharmaceutical companies, including Eli Lilly and Company and Pfizer. During his tenure at Eli Lilly, Dr. Zerbe’s clinical research and development positions included Managing Director, Lilly Research Center U.K., and Vice President of Clinical Investigation and Regulatory Affairs. He joined Parke‑Davis in 1993, becoming Senior Vice President of Worldwide Clinical Research and Development. In this capacity, Dr. Zerbe led the clinical development programs for a number of key products, including Lipitor® and Neurontin®. Dr. Zerbe received his M.D. from the Indiana University School of Medicine and he has completed post‑doctoral work in internal medicine, endocrinology and neuroendocrinology at Indiana University and the National Institutes of Health. Dr. Zerbe serves on the boards of directors of Metabolic Solutions Development Company and Cirius Therapeutics, both private companies focusing on metabolic diseases.
Alan L. Rubino
Director since September 2005
Mr. Rubino has served as President and Chief Executive Officer of RenovaCare, Inc., a publicly held biotechnology company, since November 2019. Prior to RenovaCare, Mr. Rubino served as Chief Executive Officer and President of Emisphere Technologies, Inc., Chief Executive Officer and President of New American Therapeutics, Inc., Chief Executive Officer and President of Akrimax Pharmaceuticals, LLC, and President and Chief Operating Officer of Pharmos Corporation. Mr. Rubino has continued to expand upon a highly successful and distinguished career that includes Hoffmann‑La Roche, Inc., where he was a member of the U.S. Executive and Operating Committees and an executive officer. During his Hoffman-La Roche tenure, Mr. Rubino held a series of key executive positions in marketing, sales, business operations, supply chain and human resource management and was assigned executive committee roles in marketing, project management, and globalization of the worldwide pharmaceuticals business. Mr. Rubino has also held senior executive positions at PDI, Inc. and Cardinal Health Mr. Rubino holds a B.A. in economics from Rutgers University with a minor in biology/chemistry and has completed post‑graduate educational programs at the University of Lausanne and Harvard Business School. Mr. Rubino currently serves as a member of the boards of directors of SANUWAVE Health, Inc. and Genisphere, Inc.
Director since August 2013
Heidi M. Hagen is Co-Founder of, and Advisor to, Vineti, Inc., a privately‑held company that develops and commercializes cloud‑based software platforms for ordering, manufacturing and delivering personalized medicines. Previously, Ms. Hagen served as interim Chief Commercial Officer at ZappRx, Inc. from January 2015 to June 2015. Ms. Hagen also served as Global Chief Operating Officer at Sotio LLC, a biotechnology company developing new therapies for the treatment of cancer and autoimmune diseases using its immunotherapy platform and proprietary cell‑based technologies, from March 2013 to April 2014. Before joining Sotio, Ms. Hagen served for ten years as Senior Vice President of Operations at Dendreon Corporation, where she was responsible for manufacturing and supply chain operations. Prior to joining Dendreon, Ms. Hagen spent nearly ten years at Immunex Corporation, where she held several positions in drug development and supply chain and operations management. Since June 2019, Ms. Hagen has served as a member of the boards of directors of Ziopharm Corporation, a publicly held company focused on developing the next generation of immuno-oncology gene and cell therapies, and Lykan Biosciences, a privately-held company focused on cell and gene manufacturing. Ms. Hagen earned a B.S. in cell and molecular biology, M.S. in bioengineering, and MBA from the University of Washington.
Steven Gilman, Ph.D.
Director since January 2015
Dr. Steven Gilman has been a member of the Vericel Board of Directors since 2015. Dr. Gilman served as the Chairman of the board of directors and Chief Executive Officer of ContraFect Corporation until his retirement in April 2019. He previously served as Executive Vice President, Research & Development and Chief Scientific Officer at Cubist Pharmaceuticals from September 2010 until its acquisition by Merck & Co., in January 2015. Prior to joining Cubist, Dr. Gilman served as Chairman of the board of directors and Chief Executive Officer of ActivBiotics, Inc., a privately-held biopharmaceutical company. Dr. Gilman worked at Millennium Pharmaceuticals, Inc., where he held a number of senior leadership roles, including Vice President and General Manager, Inflammation. Prior to Millennium, he was Group Director at Pfizer Global Research and Development and has also held scientific, business, and academic appointments at Wyeth Pharmaceuticals, Inc., Cytogen Corporation, Temple Medical School, and Connecticut College. Dr. Gilman currently serves on the boards of directors of ContraFect Corporation, SCYNEXIS, Inc., Akebia Therapeutics, Inc. and Momenta Pharmaceuticals, Inc. Dr. Gilman earned a B.A. in microbiology from Miami University of Ohio and Ph.D. and M.S. degrees in microbiology from Pennsylvania State University. He is an author of over 60 publications and seven U.S. patents.
Director since January 2015
Kevin McLaughlin is Senior Vice President, Chief Financial Officer and Treasurer of Acceleron Pharma – a position he has held since 2010. Previously, Mr. McLaughlin served as Senior Vice President and Chief Financial Officer of Qteros, Inc., a cellulosic biofuels company. He was also a Co-founder of Aptius Education, Inc., a publishing services company, and from 2007 through 2009, served as the Chief Operating Officer and a director. From 1996 through 2007, Mr. McLaughlin held several executive positions with PRAECIS Pharmaceuticals, Inc. He joined PRAECIS as their first Chief Financial Officer where he had responsibility for private financings, partnership financings and the company’s initial public offering. Later, Mr. McLaughlin became Chief Operating Officer, and then President and Chief Executive Officer, while serving as a member of the board of directors. In this capacity, he was responsible for negotiating the sale of the company to GlaxoSmithKline. He began his career in senior financial roles at Prime Computer and Computervision Corporation. Mr. McLaughlin is also a member of the board of directors and Chairman of the audit committee of Stealth Biotherapeutics Corp. Mr. McLaughlin received a B.S. in business from Northeastern University and an MBA from Babson College.
Paul Wotton, Ph.D.
Director since January 2015
Dr. Paul Wotton is Chief Executive Officer and a member of the board of directors of Obsidian Therapeutics, Inc. – a position he has held since April 2019. Previously, Dr. Wotton was the founding President and Chief Executive Officer of Sigilon Therapeutics, Inc., a privately held cell therapeutics company, which began in May 2016. Prior to that, Dr. Wotton served as the President, Chief Executive Officer and a member of the board of directors of Ocata Therapeutics, Inc. until its acquisition by Astellas Pharma US, Inc. in February 2016. Prior to Ocata, he served as President and Chief Executive Officer and as a member of the board of directors of Antares Pharma, Inc., as Chief Executive Officer of Topigen Pharmaceuticals, and as the Global Head of Business Development of SkyePharma PLC. Earlier in his career, Dr. Wotton held senior level positions at Eurand International BV, Penwest Pharmaceuticals, Abbott Laboratories and Merck, Sharp and Dohme. Dr. Wotton serves as Chairman of the board of directors of Cynata Therapeutics Limited and is also past Chairman of the Emerging Companies Advisory Board of BIOTEC Canada. In 2014, Dr. Wotton was named Ernst & Young Entrepreneur of the Year for Life Sciences, New Jersey. Dr. Wotton received his Bachelor’s in Pharmacy, with honors, from University College London, his Ph.D. in pharmaceutical sciences from the University of Nottingham, and his MBA from Kingston Business School.
President & CEO
Nick joined Vericel in 2013 with more than twenty years of executive management and corporate development experience in the biopharmaceutical industry, including nearly a decade with Eli Lilly and Company. During his career, he has held a variety of executive positions of increasing responsibility in product development, pharmaceutical operations, sales and marketing, and corporate development. He has extensive experience in the acquisition, development, and commercialization of products across a variety of therapeutic areas. During his tenure at Eli Lilly and Company, Nick held positions as Director of Strategy and Business Development for Lilly’s Diabetes Product Group and also served as a founding Managing Director of Lilly Ventures. Nick received his B.S.B.A. in Accounting, Magna Cum Laude, from the State University of New York at Buffalo and a J.D. degree, with Honors, from the Duke University School of Law.